Drugs / 18-Methoxycoronaridine
Trials 2 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 11 trial | ||||||
| Phase 1 | NCT04292197 | Apr 2020 → Dec 2021 | substance dependence | Definium Therapeutics US, Inc. | Completed | No outcome recorded |
| Phase 21 trial | ||||||
| Phase 2 | NCT03084952 | May 2021 → Dec 2023 | cutaneous leishmaniasis, drug-induced mental disorder | Infan Industria Quimica Farmaceutica Nacional | Unknown | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | 18-Methoxycoronaridine | “A Study to Assess 18-Methoxycoronaridine (18-MC HCl) in Healthy Volunteers” NCT04292197 ↗ |
| Known as | 18-MC HCl | “A Phase 1, Double-Blind, Randomized, Placebo-Controlled, Single/Multiple Day Dose Study to Assess the Safety, Tolerability, and Pharmacokinetics of 18- Methoxycoronaridine...” NCT04292197 ↗ |
| Route | Oral | “Administered Orally” NCT04292197 ↗ |